SMMT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Summit Therapeutics Inc (SMMT) is not a strong buy for a beginner investor with a long-term strategy at this moment. The stock lacks strong technical momentum, has no significant proprietary trading signals, and faces competition in its target market. Financials show improvement in net income and EPS but remain negative overall. Analysts' ratings are mixed, and there are no recent significant insider or institutional trades to suggest strong confidence. For now, holding off on buying is advisable.
The MACD is slightly positive but contracting, suggesting a lack of strong upward momentum. RSI is neutral at 40.099, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 14.75, with resistance at 15.491 and support at 14.009. Overall, the technical indicators suggest a neutral to slightly bearish trend.
The EGFR-NSCLC market is projected to grow significantly, with increasing demand for targeted therapies. Analysts see potential opportunities for Summit in different tumor types, and Barclays upgraded the stock with a higher price target of $18.
The competition in the EGFR-NSCLC market is intensifying with new drugs and therapies entering clinical trials. Wolfe Research expressed skepticism about the success of Summit's Harmoni-2 trial. Additionally, the company's financials remain negative despite improvement.
In Q3 2025, revenue remained at $0, with no growth. Net income improved by 312.05% YoY but remains negative at -$231.79 million. EPS also improved by 287.50% YoY but is still negative at -0.31. Gross margin is 0, indicating no profitability yet.
Barclays upgraded the stock to Equal Weight from Underweight with a price target increase to $18, citing potential in lung cancer updates and opportunities in other tumor types. Wolfe Research initiated coverage with a Peer Perform rating, expressing concerns about the success of the Harmoni-2 trial.
